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Abstract
The ReninAAV db/db uNx model of diabetic kidney disease (DKD) exhibits hallmarks of advanced human disease, including pro-
gressive elevations in albuminuria and serum creatinine, loss of glomerular filtration rate, and pathological changes. Microarray
analysis of renal transcriptome changes were more similar to human DKD when compared to db/db eNOS/ model. The model
responds to treatment with arterial pressure lowering (lisinopril) or glycemic control (rosiglitazone) at early stages of disease. We
hypothesized the ReninAAV db/db uNx model with advanced disease would have residual disease after treatment with lisinopril,
rosiglitazone, or combination of both. To test this, ReninAAV db/db uNx mice with advanced disease were treated with lisinopril,
rosiglitazone, or combination of both for 10 weeks. All treatment groups showed significant lowering of urinary albumin to
creatinine ratio compared to baseline; however, only combination group exhibited lowering of serum creatinine. Treatment
improved renal pathological scores compared to baseline values with residual disease evident in all treatment groups when
compared to db/m controls. Gene expression analysis by TaqMan supported pathological changes with increased fibrotic and
inflammatory markers. The results further validate this model of DKD in which residual disease is present when treated with agents
to lower arterial pressure and glycemic control.
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Introduction
Diabetic kidney disease (DKD) is the major cause of renal
failure in the United States, with blockade of the renin angio-
tensin system remaining the only available therapy for this
devastating disease. The prevalence of DKD and burden on
health-care systems continues to rise, with little improvements
for the treatment of DKD. Only recently, clinical data suggest
sodium-glucose co-transporter 2 inhibitors play a beneficial
role in DKD (Wanner et al. 2016). One factor impeding the
development of novel therapeutics is the lack of animal models
that mimic the human disease and progress to renal failure.
Most available models focus on the early manifestations of
DKD, proteinuria, and pathology. In contrast, clinical registra-
tion of a drug for the treatment of DKD requires demonstration
of reduced creatinine doubling events, death, or dialysis, with
proteinuria reduction alone being insufficient.
Recently, a novel murine model of progressive DKD was
generated by inducing hypertension via ReninAAV in db/db
uNx mice (Harlan et al. 2018). The ReninAAV db/db uNx
model has many physiological features of advanced human
DKD including robust proteinuria, decline in glomerular filtra-
tion rate (GFR), and increased serum creatinine and blood urea
nitrogen (Harlan et al. 2018). Histopathological assessment of
the model identified extensive mesangial matrix expansion,
arteriolar hyalinosis, and tubular interstitial fibrosis and inflam-
mation (Harlan et al. 2018). Transmission election microscopy
identified basement membrane thickening and ultrastructural
changes observed in human DKD (Harlan et al. 2018).
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Testing the effects of standard of care (SOC) in the model
would provide critical information regarding whether the
model responds to treatments similar to human patients.
To address this, the present study tested the effects of
glucose-lowering (rosiglitazone), arterial pressure–lowering
(lisinopril), or a combination of both glucose and arterial pres-
sure–lowering agents in mice with advanced disease. The
effect of these treatments in the ReninAAV db/db uNx model
was assessed by examining physiological, renal pathology, and
changes in gene expression in the kidney. The overall goal of
these studies was to identify whether SOC therapies could
attenuate or even abolish disease in the model. Information
gleaned from these experiments in the model provides a basis
for testing novel therapeutics when given with SOC.
Material and Method
Animals
All animal procedures were performed under approved Insti-
tutional Animal Care and Use Protocol. Animals were pur-
chased from the following vendors: Harlan/Envigo (db/db KS
with or without vendor performed surgical removal of one
kidney at 4–5 weeks of age and db/m controls, Indianapolis,
IN, USA). Mice were fed ad libitum a standard 5008 diet (Lab
Diets). In some studies, water was supplemented with lisino-
pril (100 mg/L, Sigma, St. Louis, MO, USA) or fed a custom
diet of 0.005% Rosiglitazone (Adipogen) supplemented 5008
diet (Lab Diets). Female db/db mice were used to reduce the
risk of hyperglycemic-induced pyelonephritis based on ana-
tomical difference rendering males more prone to
pyelonephritis.
In Vivo Assessment of ReninAAV on DKD Progression
ReninAAV and LacZAAV were previously generated (Harlan
et al. 2015). Mice received a single retro-orbital injection of
ReninAAV (5 109 GC/animal, doses based on previous stud-
ies) or LacZAAV at approximately 12 weeks of age (Harlan
et al. 2015). The following parameters were measured after 9
weeks postinjection for randomization: body weight, albumin
to creatinine ratio (ACR), and serum creatinine as previously
described (Harlan et al. 2015). Treatment started 10 weeks
post-AAV injection and mice followed with ACR measure-
ments every 2 weeks, systolic blood pressure after 4 weeks
of treatment using tail cuff plethysmography, and body weight
every 4 weeks. Rosiglitazone treatment was administered in the
diet at the concentration of 0.005% in 5008 diet ad libitum (Lab
Diets). Lisinopril was administered ad libitum in the drinking
water at 100 mg/L (Sigma). Treatment duration lasted 10
weeks for all treatment groups. Serum and plasma were col-
lected at necropsy for the measurement of serum creatinine
(enzymatic creatinine using a protocol validated by high-
performance liquid chromatography) and glucose (Harlan
et al. 2015).
Histopathological Evaluation
Formalin-fixed kidneys were transversely trimmed, routinely
processed, paraffin-embedded, microtomed at a thickness of
5 mm, and stained with H&S, Masson’s trichome (MTS), or
Periodic acid–Schiff (PAS) as previously described (Harlan
et al. 2018) Tissue sections were examined by light
microscopy and graded by board-certified veterinary pathol-
ogists. Jones’s methenamine silver staining was performed in
deparaffinized sections using standard protocol. In brief,
slides were soaked in 0.5% periodic acid for 15 min, washed,
and stained using freshly prepared methenamine silver
working solution prewarmed to 62C for 50–55 min. Slides
were rinsed, dipped in 0.2% gold chloride for 10 dips,
and then rinsed. Slides were treated with 3% sodium thio-
sulfate for 10 dips followed by rinse. Slides were counter-
stained in 0.02% light green for 1.5 min and processed for
mounting. Quantification of mesangiolysis and dilation of
glomerular tufts with alterations of capillary walls (microa-
neurysms) were performed by board-certified veterinary
pathologist.
TaqMan Analysis of Renal Cortex RNA
Trizol reagent was used to isolate the total RNA from the
kidney (Thermo Fisher Scientific, Waltham, MA, USA).
Equal concentrations of total RNA were synthesized from
each sample using SuperScript III First-Strand Synthesis Sys-
tem kit (Thermo Fisher Scientific, Waltham, MA, USA).
Real-time PCR was performed on the TaqMan real-time PCR
(7900HT; Applied Biosystems, Foster City, CA, USA)
using the TaqMan Master mix and RNA primers for mouse
S18 (Mm02601778), glyceraldehyde 3-phosphate dehydro-
genase (GAPDH; Mm99999915), collagen 4 COL4a1
(Mm01210125), collagen I COL1a1 (Mm00801666), fibro-
nectin 1 Fn1 (Mm01256744), macrophage marker F4/80
(Mm00802529), vimentin (Mm01333430), monocyte che-
moattractant protein 1 MCP-1 (Mm00441242), tumor necro-
sis factor alpha (TNF-a; Mm00443258), and transforming
growth factor beta (TGF-b; Mm00441726).
Statistical Analysis
Statistical analysis of physiological and pathological para-
meters was calculated by compared treatment groups to base-
line peel off groups using standard t test; p < .05 was
considered statistically relevant. Combination treatments
were further compared to rosiglitazone- and lisinopril-
treated groups to see whether significant further reduction
in parameters were observed with combination treatment (t
test, p < .05 statistically relevant). For gene expression anal-
ysis, RNA from healthy controls and db/m and db/db uNx
LacZ controls were included. RNA from ReninAAV db/db
uNx-baseline mice were first compared to db/m and the LacZ
controls for statistical relevance (t test, p < .05 statistically
relevant). RNA from treatment groups were then compared to
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db/m, db/db uNx LacZ, and ReninAAV db/db uNx-baseline
mice (t test, p < .05 statistically relevant). For gene expression
analysis, Taqman was ran in triplicate for each mouse with
N ¼ 3 mice per group.
Results
Effects of Glucose and Arterial Pressure–Lowering Agents
in the Model
The effects of glucose-lowering or arterial pressure–lowering
agents on the ReninAAV db/db uNx model with advanced
disease were tested by treating mice with rosiglitazone, lisino-
pril, or a combination of rosiglitazone and lisinopril (combina-
tion). Mice received a single retro-orbital injection of
ReninAAV at 12 weeks of age and followed for 10 weeks
before treatments started. A cohort of untreated mice were
sacrificed at 10 weeks post-ReninAAV injection for baseline
comparison. Interim arterial pressure measurement after four
weeks of treatment using tail cuff plethysmography demon-
strated lisinopril significantly (p < .01) lowered systolic
arterial pressure (SAP) (136 + 12 mmHg lisinopril only,
125 + 9 mmHg combination) as compared to rosiglitazone
(180 + 8 mmHg)-treated mice (Figure 1A). Urine ACR sig-
nificantly (p < .05) decreased when compared to baseline
pretreatment values (36,567 + 2,237 μg/mg) in both the
lisinopril (12,547 + 2,639 μg/mg) and combination
(16,308 + 4,798 μg/mg) groups after 2 weeks of treatment
and significantly decreased in the rosiglitazone (21,199 +
3,218 μg/mg)-treated group after 4 weeks of treatment (Fig-
ure 1B). All groups ACR remained significantly reduced for
the duration of treatment period.
Serum was collected at baseline 10 weeks post-ReninAAV
and after 10 weeks of treatment to assess the effects of
treatment on renal function using serum creatinine as an
indicator of renal function. After 10 weeks of ReninAAV,
the baseline peel off group had an average serum creatinine
of 0.16 + 0.02 mg/dl, which is consistent with published
work on the model in which elevations in serum
creatinine were evident starting at 8 weeks post-
ReninAAV injections (LacZ db/db uNx controls 0.08 +
0.01 mg/dl). Treatment for 10 weeks with lisinopril or rosi-
glitazone only halted any further increase in serum creati-
nine as there was not a significant difference from baseline
(0.18 + 0.02 mg/dl and 0.17 + 0.02 mg/dl, respectively;
Figure 1C). Combination treatment with both rosiglitazone
and lisinopril led to significant lowering of serum creatinine
(0.13 + 0.01 mg/dl, p < .05) compared to baseline pretreat-
ment values as well as compared to rosiglitazone- or lisino-
pril only-treated cohorts.
Pathological Changes with Lisinopril or Rosiglitazone
Treatment
Pathological assessment was performed using standard histo-
pathological examination (H&S, MTS, and PAS) and Jones’s
Figure 1. Effects of arterial pressure and glucose-lowering agents in
the ReninAAV db/db uNx model. (A) Treatment with lisinopril either
alone or in combination with rosiglitazone led to significant reductions
in arterial pressure as compared to rosiglitazone-only-treated mice.
(B) Treatment with lisinopril and combination treatment significantly
lowered albumin to creatinine ratio (ACR) after two weeks of treat-
ment and remained significantly reduced the duration of treatment.
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methenamine silver staining. Rosiglitazone-treated mice had
similar histopathological scores as compared to the vehicle-
treated peel off group, consistent with the modest effects on
ACR lowering, with only a significant reduction in mesangial
matrix expansion in the rosiglitazone-treated mice observed
(Figure 2A). Lisinopril- and combination-treated mice had sig-
nificant improvements in all histopathological parameters mea-
sured as compared to the baseline controls (Figure 2A and B).
The combination group did not exhibit further improvements in
pathological changes compared to the lisinopril-only group,
except for a further reduction in mesangial matrix expansion
(Figure 2A).
Jones’s staining was performed to identify whether the
model exhibits mesangiolysis and/or dilation of glomerular
tufts with alterations of capillary walls (glomerular microa-
neurysm), which are pathological features of human DKD.
For this analysis, db/m and db/db uNx controls were included
as pathological assessment using Jones’s staining in the Reni-
nAAV db/db uNx model had not been assessed prior. Mesan-
giolysis and/or microaneurysm of glomerular capillary loops
was not observed in either the db/m lean or db/db uNx mice
necropsied at 22 weeks of age (Figure 3A and B). In general,
mesangiolysis and/or microaneurysm was not a prominent
feature of the ReninAAV db/db uNx model (Figure 3A, B);
however, a small percentage of the glomeruli were identified
with mesangiolysis and/or microaneurysms (Figure 3A, B).
Treatment with lisinopril led to a trend (p ¼ .07) in the
reductions in the occurrence of mesangiolysis and/or
microaneurysms which became statistically relevant in
combination-treated mice (Figure 3B).
Effects of Treatments on Fibrotic and Inflammatory
Gene Expression
Pathological evaluation of the ReninAAV db/db uNx model
indicated increased fibrosis and inflammation, which
improved with lisinopril treatment. To identify whether the
pathological changes were a result of gene expression changes
of inflammatory and fibrotic genes, TaqMan analysis of renal
cortex samples was performed using probes for inflammatory
(F4/80, TNF-a, and MCP-1) and fibrotic markers (COL1A1,
COL4A1, TGF-b, and vimentin). Consistent with our previ-
ous gene expression studies on the model (Harlan et al. 2018),
elevations in fibrotic and inflammatory genes were detected
when compared to db/m controls (Figure 4A). Treatment with
lisinopril, rosiglitazone, or combination led to significant
reduction in most fibrotic and inflammatory genes tested
(Figure 4A, B). Lisinopril treatment did not affect the expres-
sion of vimentin, where rosiglitazone and combination treat-
ment led to significant reduction when compared to
ReninAAV db/db uNx vehicle-treated mice (Figure 4).
Discussion
The ReninAAV db/db uNx model has key attributes of human
DKD with progressive elevations of ACR, doubling of serum
creatinine, decline in GFR, and pathological changes closely
mimicking human DKD (Harlan et al. 2018). Similarity to
human disease was demonstrated in that the mice respond to
glucose-lowering or arterial pressure–lowering agents with
residual disease present, resembling human DKD and
eNOS/ db/db mice (Zhang et al. 2012; Harlan et al.
2018). However, combination of both glucose and arterial
pressure–lowering agents to identify whether combination
treatment would abolish disease had not been tested and was
the focus of the present study. In addition, the effects of these
agents either singly or in combination in mice with advanced
stage disease had not been investigated prior to these studies.
The present study started treatment at advanced stage disease
(doubling of serum creatinine) to address the question
whether these agents could improve disease after more severe
pathological changes have occurred. The data demonstrate
that at advanced stage disease, rosiglitazone had modest yet
significant effect on ACR and pathology, yet was effective in
lowering expression of inflammatory and fibrotic genes sug-
gesting it only halted further disease progression. Lisinopril
treatment alone or in combination with rosiglitazone had
robust ACR-lowering effect and reduction in renal patholo-
gical changes; however, residual disease was still present
suggesting opportunity for novel therapeutics to add benefit
when treated concurrent with glucose and arterial pressure–
lowering agents.
Previous pathological characterization of the model
focused on histopathological changes and ultrastructural
changes. However, a key feature of human DKD and
previously characterized models of advanced DKD such as
the BTBR-ob/ob model is the presence of glomerular mesan-
giolysis and microaneurysms (Hudkins et al. 2010; Saito
et al. 1988). To identify whether the ReninAAV db/db uNx
model exhibited these features of DKD, renal sections
from the model and control mice were stained with Jones’s
methenamine silver stain. Pathological examination of
the staining identified that mesangiolysis and microaneur-
ysms are not a prominent feature of the model and detected
in approximately 2% of the glomeruli. These mice were
evaluated at an advanced stage in the disease; thus, it is
plausible that the extensive mesangial matrix expansion and
deposition that is occurring at this stage is overriding the
presence of the mesangiolysis and microaneurysms (Saito
et al. 1988). Future studies using kidneys from early-stage
disease (4 weeks post-ReninAAV) would provide insight
into whether this phenotype is present in the model early
on in the disease.
Figure 1. (Continued). Rosiglitazone significantly lowered ACR after
four weeks of treatment, which remained significantly reduced the
duration of the study. (C) Serum creatinine remained unchanged in
lisinopril or rosiglitazone treatment groups as compared to baseline
peel off. Combination group had significantly lower serum creatinine
compared to baseline peel off. (A) *p < .05 compared to lisinopril and
combo groups. (B and C) *p < .05 compared to baseline peel off group,
$p < .05 versus baseline and rosiglitazone.
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Figure 2. Histopathological changes in ReninAAV db/db uNx mice. (A) Quantification of the pathological changes observed in ReninAAV db/db
uNx mice treated with lisinopril, rosiglitazone, or combination. *p < .05 versus baseline; $p < .05 versus baseline and rosiglitazone; &p < .05 versus
baseline, rosiglitazone, and lisinopril. (B) Representative photomicrographs of Mason’s Trichrome-stained renal sections. ReninAAV db/db uNx
mice treated with lisinopril or combination show reduction in glomerular, periglomerular, and interstitial fibrosis compared to ReninAAV db/db
uNx mice treated with vehicle or rosiglitazone alone (Masson’s trichome).
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In conclusion, this study substantiates the importance
of hypertension and diabetes in progressive DKD. The
effects of elevated blood glucose and hypertension led
to pathological changes in the kidney that can only be
partially reversed if the blood pressure and glucose levels
are normalized. Inflammation and fibrosis that resides
after treatment likely contribute to the residual disease
present and after prolong time in human DKD patients
may contribute to the progression of end-stage renal
disease.
Figure 3. Mesangiolysis and microaneurysms in glomeruli of ReninAAV db/db uNx mice. (A) Jones’s methenamine silver staining of db/m, db/db
uNx, and ReninAAV db/db uNx mice treated with standard of care (SOC) therapies (Jones’s stain). (B) Quantification of incidence of mesangiolysis
and microaneurysms found in control and ReninAAV db/db uNx mice treated with SOC therapies. *p < .05 versus db/m and db/db uNx controls,
#p < 0.5 versus ReninAAV db/db uNx vehicle peel off group.
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